Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

Serelaxin as a potential treatment for renal dysfunction in cirrhosis: Preclinical evaluation and results of a randomized phase 2 trial.

Snowdon VK, Lachlan NJ, Hoy AM, Hadoke PW, Semple SI, Patel D, Mungall W, Kendall TJ, Thomson A, Lennen RJ, Jansen MA, Moran CM, Pellicoro A, Ramachandran P, Shaw I, Aucott RL, Severin T, Saini R, Pak J, Yates D, Dongre N, Duffield JS, Webb DJ, Iredale JP, Hayes PC, Fallowfield JA.

PLoS Med. 2017 Feb 28;14(2):e1002248. doi: 10.1371/journal.pmed.1002248. eCollection 2017 Feb.

2.

Renal hemodynamic effects of serelaxin in patients with chronic heart failure: a randomized, placebo-controlled study.

Voors AA, Dahlke M, Meyer S, Stepinska J, Gottlieb SS, Jones A, Zhang Y, Laurent D, Slart RH, Navis GJ.

Circ Heart Fail. 2014 Nov;7(6):994-1002. doi: 10.1161/CIRCHEARTFAILURE.114.001536. Epub 2014 Oct 6.

PMID:
25286914
3.

Effects of serelaxin in acute heart failure patients with renal impairment: results from RELAX-AHF.

Liu LC, Voors AA, Teerlink JR, Cotter G, Davison BA, Felker GM, Filippatos G, Chen Y, Greenberg BH, Ponikowski P, Pang PS, Prescott MF, Hua TA, Severin TM, Metra M.

Clin Res Cardiol. 2016 Sep;105(9):727-37. doi: 10.1007/s00392-016-0979-8. Epub 2016 Mar 26.

4.

Effects of serelaxin on renal microcirculation in rats under control and high-angiotensin environments.

Shao W, Rosales CB, Gonzalez C, Prieto MC, Navar LG.

Am J Physiol Renal Physiol. 2018 Jan 1;314(1):F70-F80. doi: 10.1152/ajprenal.00201.2017. Epub 2017 Oct 4.

5.

A randomized, double-blind, placebo-controlled, multicentre study to assess haemodynamic effects of serelaxin in patients with acute heart failure.

Ponikowski P, Mitrovic V, Ruda M, Fernandez A, Voors AA, Vishnevsky A, Cotter G, Milo O, Laessing U, Zhang Y, Dahlke M, Zymlinski R, Metra M.

Eur Heart J. 2014 Feb;35(7):431-41. doi: 10.1093/eurheartj/eht459. Epub 2013 Nov 18.

6.

Relaxin modulates human and rat hepatic myofibroblast function and ameliorates portal hypertension in vivo.

Fallowfield JA, Hayden AL, Snowdon VK, Aucott RL, Stutchfield BM, Mole DJ, Pellicoro A, Gordon-Walker TT, Henke A, Schrader J, Trivedi PJ, Princivalle M, Forbes SJ, Collins JE, Iredale JP.

Hepatology. 2014 Apr;59(4):1492-504. doi: 10.1002/hep.26627. Epub 2014 Mar 3.

PMID:
23873655
7.

Renal impairment and worsening of renal function in acute heart failure: can new therapies help? The potential role of serelaxin.

Schmieder RE, Mitrovic V, Hengstenberg C.

Clin Res Cardiol. 2015 Aug;104(8):621-31. doi: 10.1007/s00392-015-0839-y. Epub 2015 Mar 19. Review.

PMID:
25787721
8.

Does serelaxin treatment alter passive mechanical wall properties in small resistance arteries?

Jelinic M, Kahlberg N, Parry LJ, Tare M.

Microcirculation. 2016 Nov;23(8):631-636. doi: 10.1111/micc.12321. Review.

PMID:
27653183
9.

Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial.

Teerlink JR, Cotter G, Davison BA, Felker GM, Filippatos G, Greenberg BH, Ponikowski P, Unemori E, Voors AA, Adams KF Jr, Dorobantu MI, Grinfeld LR, Jondeau G, Marmor A, Masip J, Pang PS, Werdan K, Teichman SL, Trapani A, Bush CA, Saini R, Schumacher C, Severin TM, Metra M; RELAXin in Acute Heart Failure (RELAX-AHF) Investigators.

Lancet. 2013 Jan 5;381(9860):29-39. doi: 10.1016/S0140-6736(12)61855-8. Epub 2012 Nov 7.

PMID:
23141816
10.

Time-dependent activation of prostacyclin and nitric oxide pathways during continuous i.v. infusion of serelaxin (recombinant human H2 relaxin).

Leo CH, Jelinic M, Ng HH, Tare M, Parry LJ.

Br J Pharmacol. 2016 Mar;173(6):1005-17. doi: 10.1111/bph.13404. Epub 2016 Feb 17.

11.

B7-33 replicates the vasoprotective functions of human relaxin-2 (serelaxin).

Marshall SA, O'Sullivan K, Ng HH, Bathgate RAD, Parry LJ, Hossain MA, Leo CH.

Eur J Pharmacol. 2017 Jul 15;807:190-197. doi: 10.1016/j.ejphar.2017.05.005. Epub 2017 May 3.

PMID:
28478069
12.

Reperfusion therapy with recombinant human relaxin-2 (Serelaxin) attenuates myocardial infarct size and NLRP3 inflammasome following ischemia/reperfusion injury via eNOS-dependent mechanism.

Valle Raleigh J, Mauro AG, Devarakonda T, Marchetti C, He J, Kim E, Filippone S, Das A, Toldo S, Abbate A, Salloum FN.

Cardiovasc Res. 2017 May 1;113(6):609-619. doi: 10.1093/cvr/cvw246.

PMID:
28073832
13.

Serelaxin a novel treatment for acute heart failure.

Castrini AI, Carubelli V, Lazzarini V, Bonadei I, Lombardi C, Metra M.

Expert Rev Clin Pharmacol. 2015;8(5):549-57. doi: 10.1586/17512433.2015.1073587. Review.

PMID:
26294074
14.

Pharmacokinetics of serelaxin in patients with severe renal impairment or end-stage renal disease requiring hemodialysis: A single-dose, open-label, parallel-group study.

Dahlke M, Halabi A, Canadi J, Tsubouchi C, Machineni S, Pang Y.

J Clin Pharmacol. 2016 Apr;56(4):474-83. doi: 10.1002/jcph.607. Epub 2015 Nov 4.

15.

Acute intravenous injection of serelaxin (recombinant human relaxin-2) causes rapid and sustained bradykinin-mediated vasorelaxation.

Leo CH, Jelinic M, Parkington HC, Tare M, Parry LJ.

J Am Heart Assoc. 2014 Feb 28;3(1):e000493. doi: 10.1161/JAHA.113.000493.

16.

Serelaxin in acute heart failure: Most recent update on clinical and preclinical evidence.

Ghosh RK, Banerjee K, Tummala R, Ball S, Ravakhah K, Gupta A.

Cardiovasc Ther. 2017 Feb;35(1):55-63. doi: 10.1111/1755-5922.12231. Review.

PMID:
27727514
17.

Localization of relaxin receptors in arteries and veins, and region-specific increases in compliance and bradykinin-mediated relaxation after in vivo serelaxin treatment.

Jelinic M, Leo CH, Post Uiterweer ED, Sandow SL, Gooi JH, Wlodek ME, Conrad KP, Parkington H, Tare M, Parry LJ.

FASEB J. 2014 Jan;28(1):275-87. doi: 10.1096/fj.13-233429. Epub 2013 Sep 13.

18.

Recombinant human relaxin versus placebo for cervical ripening: a double-blind randomised trial in pregnant women scheduled for induction of labour.

Weiss G, Teichman S, Stewart D, Nader D, Wood S, Breining P, Unemori E.

BMC Pregnancy Childbirth. 2016 Sep 5;16:260. doi: 10.1186/s12884-016-1046-1.

19.

Increase of cortical cerebral blood flow and further cerebral microcirculatory effects of Serelaxin in a sheep model.

Bischoff SJ, Schmidt M, Lehmann T, Irintchev A, Schubert H, Jung C, Schwab M, Huber O, Matziolis G, Schiffner R.

Am J Physiol Heart Circ Physiol. 2016 Sep 1;311(3):H613-20. doi: 10.1152/ajpheart.00118.2016. Epub 2016 Jul 8.

20.

Serelaxin improves cardiac and renal function in DOCA-salt hypertensive rats.

Wang D, Luo Y, Myakala K, Orlicky DJ, Dobrinskikh E, Wang X, Levi M.

Sci Rep. 2017 Aug 29;7(1):9793. doi: 10.1038/s41598-017-09470-0.

Supplemental Content

Support Center